FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 324:1677-1684 June 13, 1991 Number 24 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. Despite multiple antiviral humoral and cellular immune responses, infection with the human immunodeficiency virus (HIV) results in a progressively debilitating disease. We hypothesized that a more effective immune response could be generated by post-infection vaccination with HIV-specific antigens. METHODS. We performed a phase I trial of the safety and immunogenicity of a vaccine prepared from molecularly cloned envelope protein, gp160, in 30 volunteer subjects with HIV infection in Walter Reed stage 1 or 2. The vaccine was administered either on days 0, 30, and 120 or on days 0, 30, 60, 120, 150, and 180. HIV-specific humoral and cellular immune responses were measured; local and systemic reactions to vaccination, including general measures of immune function, were monitored. RESULTS. In 19 of the 30 subjects both humoral and cellular immunity to HIV envelope proteins increased in response to vaccination with gp160. Seroconversion to selected envelope epitopes was observed, as were new T-cell proliferative responses to gp160. Response was associated with the CD4 cell count determined before vaccination (13 of 16 subjects [81 percent] with greater than 600 cells per milliliter responded, as compared with 6 of 14 [43 percent] with less than or equal to 600 cells per milliliter; P = 0.07) and with the number of injections administered (87 percent of subjects randomly assigned to receive six injections responded, as compared with 40 percent of those assigned to three injections; P = 0.02). Local reactions at the site of injection were mild. There were no adverse systemic reactions, including diminution of general in vitro or in vivo cellular immune function. After 10 months of follow-up, the mean CD4 count had not decreased in the 19 subjects who responded, but it had decreased by 7.3 percent in the 11 who did not respond. CONCLUSIONS. This gp160 vaccine is safe and immunogenic in volunteer patients with early HIV infection. Although it is too early to know whether this approach will be clinically useful, further scientific and therapeutic evaluation of HIV-specific vaccine therapy is warranted. Similar vaccines may prove to be effective for other chronic infections.

Source Information

Department of Retroviral Research, Walter Reed Army Institute of Research, Rockville, Md. 20850.

This article has been cited by other articles:

• Gorse, G. J., Simionescu, R. E., Patel, G. B. (2006). Cellular Immune Responses in Asymptomatic Human Immunodeficiency Virus Type 1 (HIV-1) Infection and Effects of Vaccination with Recombinant Envelope Glycoprotein of HIV-1. CVI 13: 26-32 [Abstract] [Full Text]  
• Jin, X., Ramanathan, M. Jr., Barsoum, S., Deschenes, G. R., Ba, L., Binley, J., Schiller, D., Bauer, D. E., Chen, D. C., Hurley, A., Gebuhrer, L., El Habib, R., Caudrelier, P., Klein, M., Zhang, L., Ho, D. D., Markowitz, M. (2002). Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy. J. Virol. 76: 2206-2216 [Abstract] [Full Text]  
• Essajee, S. M., Yogev, R., Pollack, H., Greenhouse, B., Krasinski, K., Borkowsky, W. (2002). Recombinant Glycoprotein Vaccines for Human Immunodeficiency Virus-Infected Children and Their Effects on Viral Quasispecies. CVI 9: 79-82 [Abstract] [Full Text]  
• Ansari, A. F., Etzel, J. V. (2000). Immune-Based Therapies for the Management of HIV Infection: Highly Active Antiretroviral Therapy and Beyond. Journal of Pharmacy Practice 13: 515-532 [Abstract]  
• Leandersson, A.-C., Gilljam, G., Fredriksson, M., Hinkula, J., Alaeus, A., Lidman, K., Albert, J., Bratt, G., Sandstrom, E., Wahren, B. (2000). Cross-Reactive T-Helper Responses in Patients Infected with Different Subtypes of Human Immunodeficiency Virus Type 1. J. Virol. 74: 4888-4890 [Abstract] [Full Text]  
• Calarota, S. A., Leandersson, A.-C., Bratt, G., Hinkula, J., Klinman, D. M., Weinhold, K. J., Sandstrom, E., Wahren, B. (1999). Immune Responses in Asymptomatic HIV-1-Infected Patients After HIV-DNA Immunization Followed by Highly Active Antiretroviral Treatment. J. Immunol. 163: 2330-2338 [Abstract] [Full Text]  
• Edwards, D. M., Shachter, R. D., Owens, D. K. (1998). A Dynamic HIV-Transmission Model for Evaluating the Costs and Benefits of Vaccine Programs. Interfaces 28: 144-166 [Abstract]  
• Graham, B. S., Wright, P. F. (1995). Candidate AIDS Vaccines. NEJM 333: 1331-1339 [Full Text]  
• Letvin, N. L. (1993). Vaccines against Human Immunodeficiency Virus -- Progress and Prospects. NEJM 329: 1400-1405 [Full Text]  
• Hirsch, M. S., D'Aquila, R. T. (1993). Therapy for Human Immunodeficiency Virus Infection. NEJM 328: 1686-1695 [Full Text]  
• Stoeckle, M. Y., Douglas, R. G. Jr (1992). Infectious Diseases. JAMA 268: 366-368 [Abstract]  
• Takahashi, H, Nakagawa, Y, Pendleton, C., Houghten, R., Yokomuro, K, Germain, R., Berzofsky, J. (1992). Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. Science 255: 333-336 [Abstract]  
• (1991). VACCINE BOOSTS IMMUNITY IN EARLY HIV INFECTION. JWatch General 1991: 5-5 [Full Text]